Immuno-Designed Molecules which specialises in cancer drugs has filed to float in France despite the sector's poor initial public offering performance in both Europe and the US. It pulled its Paris float two years ago but has now appointed UBS.

Immuno-Designed Molecules declined to comment on the share offer size, expected valuation or timing of the deal. At its last attempt to go public, it set out to raise between €100m ($122m) and €150m.